Professor Margaret Y. M Lartey

I am a Physician with specialist training and interests in Dermatology and Infectious Diseases. My scholarly works have been mainly in Infectious Diseases with few in Dermatology even though I actively practiced both disciplines. Prior to becoming Dean, I was the Head of Department for Medicine and Therapeutics for two years and Head of the Infectious Diseases Unit for 10 years as well of Head of the Dermatology Unit for 10 years.

My research areas include the skin and HIV, HIV Co-infections, Pharmacokinetics and Pharmacogenetics of Efavirenz in HIV and TB infected persons, HIV Drug Resistance, HIV associated behavior (adherence, stigma, disclosure, employment, engagement with health sector) and elimination of mother to child transmission (EMTCT).  I have also researched various aspects of antiretroviral therapy. My research areas also include hepatitis, tuberculosis, cryptococcosis, rabies, Ebola and tetanus.  I have also researched into aspects of paediatric and adolescent  HIV infections.

 In my work as an infectious disease physician,  I  supervise and train doctors, nurses and other health workers in the clinical management of HIV infection cutting across adolescents and adults, paediatrics, MTCT, laboratory diagnoses, nutrition, counseling and testing. I teach both undergraduate medical students, residents and postgraduate students in the medical school and teaching hospital. I supervise Masters, Doctoral and post-doctoral students in allied disciplines. I have attended many local and international conferences, some of which I have made oral and poster presentations.

A few of my publications are presented below:

1.    Archampong T.N.A., Boyce C.L., Lartey M., Sagoe K.W., Obo-Akwa A., Kenu E., Blackard J.T., Kwara A. (2016). HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV-co-infected patients. Anti Vir Ther; PMID: 27167598; doi: 10.3851/IMP3055.

 

2.    Kwamena William Coleman Sagoe, Kwabena Obeng Duedu, Francesca Ziga, Afrakoma Adjoa Agyei, Theophilus Korku Adiku, Margaret Lartey, Julius Abraham Addo Mingle and Max Arens. Short‑term treatment outcomes in human immunodeficiency virustype‑1 and hepatitis B virus co‑infections. Ann Clin Microbiol Antimicrob (2016) 15:38 DOI 10.1186/s12941-016-0152-

 

3.    Daniel NA Ankrah, Ellen S Koster, Aukje K Mantel-Teeuwisse ,Daniel K Arhinful, Irene A Agyepong, Margaret Lartey. Facilitators and barriers to antiretroviral therapy adherence among adolescents in Ghana.  Patient Preference and Adherence 2016:10 329–337

 

4.    Edward K. Maina , C.Z. Abana , E.A. Bukusi , M. Sedegah , M. Lartey , W.K. Ampofo. Plasma concentrations of transforming growth factor beta 1in non-progressive HIV-1 infection correlates with markers of disease progression. Cytokine 81 (2016) 109–116

 

5.    Archampong  Timothy, Lartey  Margaret, Sagoe  Kwamena, Obo-Akwa  Adjoa, Kenu  Ernest, Gillani  Fizza, Yang  Hongmei, Boamah  Isaac, Flanigan  Timothy, Kwara  Awewura. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naive and experienced HIV co-infected Ghanaian patients. BMC Infectious Diseases (2016) 16:14 DOI: 10.1186/s12879-016-1342-4

 

6.    Ankrah DNA, Lartey M, Agyepong I, Hubert GM, Mantel-Teeuwisse AK (2015) Adherence and Treatment Change among HIV/AIDS Patients in Ghana – A Nested Case Control Study. J AIDS Clin Res 6: 510. doi:10.4172/2155-6113.1000510

 

7.     Margaret Lartey, Peter Puplampu, Nana Ayegua Hagan Seneadza, Joseph Oliver-Commey, Serwah Amoah, Sally-Ann Ohene. Preparing for Ebola, the experiences of a national training team (Ghana). Pan Afr Med J. 2015;22(Supp 1):12   DOI:10.11694/pamj.supp.2015.22.1.6320

 

8.    E.K. Maina, E.Y. Bonney, E.A. Bukusi, M. Sedegah, M. Lartey, W.K. Ampofo. CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies, Immunol Lett (2015), http://dx.doi.org/10.1016/j.imlet.2015.10.005

 

9.    Stephanie Bjerrum, Ernest Kenu, Margaret Lartey, Mercy Jemina Newman, Kennedy Kwasi Addo, Aase Bengaard Andersen and Isik Somuncu Johansen. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana–findings from the DETECT     HIV-TB study. BMC Infectious Diseases (2015) 15:407

 

10. Nancy R. Reynolds, Angela Ofori-Atta, Margaret Lartey, Lorna Renner, Sampson Antwi, Anthony Enimil, Ann Christine Catlin, Sumudinie Fernando,Tassos C. Kyriakides and Elijah Paintsil. SANKOFA: a multisite collaboration on paediatric HIV disclosure in Ghana. AIDS 2015:29 (Suppl 1); S35–S45. DOI:10.1097/QAD.0000000000000725   

 

11. M. Lartey, A. Asante-Quashie, A. Essel, E. Kenu, V. Ganu and A. Neequaye.  Causes of death in hospitalized HIV patients in the early anti-retroviral therapy era. Ghana Med J 2015: 49 (1); 7-11. DOI: http://dx.doi.org/10.4314/gmj.v49i1.2 .  

 

12. KP Akakpo, SE Quayson and M Lartey. Disseminated cryptococcosis in a patient with HIV/AIDS at a teaching hospital in Ghana. SAGE Open Medical Case Reports 2015. DOI: 10.1177/2050313X14565421

 

13. Awewura Kwara,  Margaret Lartey,  Isaac Boamah, ,Naser L. Rezk,  Joseph   Oliver-Commey,  Ernest Kenu, ,Angela D. M. Kashuba,  Michael H. Court.  Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation. J. Clin. Pharmacol. 2009; 49; 1079-1090

 

14. Awewura Kwara, Margaret Lartey, Kwamena W Sagoe, Naser L Rzek, Michael  H Court. CYP2B6 (c.516G>T) and CYP2A6 (*9B and/or *17) Polymorphisms are Independent Predictors of Efavirenz Plasma Concentrations in HIV-infected Patients.Br J Clin Pharmacol 2009; 67:4,427-436

 

15. Kwara A, Lartey M, Sagoe KWC, Xexemeku F, Kenu E, Oliver-Commey J, Boima V,      Sagoe A, Boamah I, Greenblatt DJ, Court MH.  Pharmacokinetics of Efavirenz When Co-Administered With Rifampin in TB/HIV Co-Infected Patients: Pharmacogenetic Effect of CYP2B6 Variation. J Clin Pharmacol 2008;48:1032-1040

 

 

 

 

 

 

 

 

 

 

 

Position: 
Dean SMD
Qualification: 
MBChB, MSc, MPH, FGCPS, FWACP.